Neil Exter serves as Independent Director of the Company. Mr. Exter previously served as a member of our board of directors from November 2014 to March 2016. Mr. Exter has been a Partner at Third Rock Ventures since 2007. Prior to joining Third Rock Ventures, Mr. Exter was Chief Business Officer of Alantos Pharmaceuticals from 2006 until its acquisition by Amgen in 2007. Previously, he served as Vice President of Business Development for Millennium Pharmaceuticals from 2002 to 2006. Mr. Exter previously served as a member of the boards of directors of CytomX Therapeutics, a biopharmaceutical company, from December 2010 to December 2017, and Rhythm Pharmaceuticals, a biopharmaceutical company, from 2014 to June 2019. He is a member of the Research Committee of Children’s Hospital Boston, the investment committee of the Innovation Research Fund at Partners Healthcare, and the board of directors of the New England Venture Capital Association. Mr. Exter received a B.S. from Cornell University, an M.S. from Stanford University, and an M.B.A. as a Baker Scholar from Harvard Business School.
Neil's mailing address filed with the SEC is C/O PLIANT THERAPEUTICS, INC., 260 LITTLEFIELD AVENUE, SOUTH SAN FRANCISCO, CA, 94080.
Over the last 5 years, insiders at Revolution Medicines Inc have traded over $249,645,422 worth of Revolution Medicines Inc stock and bought 3,371,315 units worth $74,500,278 . The most active insiders traders include Peter Svennilson, Thilo Schroeder и Rock Ventures Ii, L.P.Third.... On average, Revolution Medicines Inc executives and independent directors trade stock every 11 days with the average trade being worth of $3,075,216. The most recent stock trade was executed by Stephen Michael Kelsey on 13 August 2024, trading 16,667 units of RVMD stock currently worth $68,168.
revolution medicines discovers and develops new drugs that harness the therapeutic potential of frontier oncology targets on behalf of cancer patients. our innovative product engine draws inspiration from nature and evolution, which offer insights into cancer targets, disease mechanisms and therapeutic approaches. we pay particular attention to natural products that are inherently rich with biological function as a result of natural selection and can inform and guide our discovery and development of small molecules that can modulate these targets.
Revolution Medicines Inc executives and other stock owners filed with the SEC include: